全文获取类型
收费全文 | 501篇 |
免费 | 28篇 |
国内免费 | 15篇 |
专业分类
儿科学 | 28篇 |
妇产科学 | 4篇 |
基础医学 | 47篇 |
口腔科学 | 7篇 |
临床医学 | 32篇 |
内科学 | 134篇 |
皮肤病学 | 5篇 |
神经病学 | 11篇 |
特种医学 | 90篇 |
外科学 | 38篇 |
综合类 | 7篇 |
预防医学 | 24篇 |
眼科学 | 6篇 |
药学 | 41篇 |
肿瘤学 | 70篇 |
出版年
2022年 | 3篇 |
2021年 | 4篇 |
2020年 | 2篇 |
2019年 | 3篇 |
2018年 | 10篇 |
2017年 | 7篇 |
2016年 | 9篇 |
2015年 | 10篇 |
2014年 | 9篇 |
2013年 | 23篇 |
2012年 | 14篇 |
2011年 | 12篇 |
2010年 | 22篇 |
2009年 | 20篇 |
2008年 | 20篇 |
2007年 | 25篇 |
2006年 | 22篇 |
2005年 | 14篇 |
2004年 | 10篇 |
2003年 | 9篇 |
2002年 | 11篇 |
2001年 | 9篇 |
2000年 | 5篇 |
1999年 | 11篇 |
1998年 | 25篇 |
1997年 | 28篇 |
1996年 | 30篇 |
1995年 | 22篇 |
1994年 | 25篇 |
1993年 | 18篇 |
1992年 | 9篇 |
1991年 | 3篇 |
1990年 | 7篇 |
1989年 | 11篇 |
1988年 | 7篇 |
1987年 | 9篇 |
1986年 | 11篇 |
1985年 | 5篇 |
1984年 | 4篇 |
1983年 | 4篇 |
1982年 | 5篇 |
1981年 | 9篇 |
1980年 | 7篇 |
1979年 | 2篇 |
1978年 | 2篇 |
1977年 | 4篇 |
1976年 | 10篇 |
1975年 | 3篇 |
排序方式: 共有544条查询结果,搜索用时 0 毫秒
91.
Subcellular localization of transforming growth factor-alpha in human eosinophil granulocytes 总被引:1,自引:1,他引:0
Eosinophils are involved in the inflammatory response seen in allergy and helminthic infestations. Eosinophils synthesize transforming growth factor-alpha (TGF-alpha), which may play a role in the development of the characteristic fibrosis seen in longstanding high eosinophilia. Using immunoelectron microscopic techniques, eosinophils from peripheral blood of healthy individuals and from one patient with high eosinophilia showed presence TGF-alpha in matrix of the specific crystalloid-containing granules. In cryosections, TGF-alpha was also visualized in a vesicular compartment of the cytoplasm. In double- labeling experiments, the TGF-alpha of this latter compartment did not colocalize with CD63, a marker for lysosomes, nor with albumin of secretory vesicles. In extracts from eosinophils, obtained from healthy donors, immunoreactive TGF-alpha could be detected by enzyme-linked immunosorbent assay-technique. In addition, sera from two patients with high eosinophilia showed TGF-alpha concentrations of 1.5 ng/mL and 164 pg/mL, respectively, whereas TGF-alpha could not be detected in serum from healthy controls. In conclusion, TGF-alpha is present in the specific granules, and in an additional vesicular compartment of the cytoplasm of eosinophils. 相似文献
92.
Primitive hematopoietic cells released into the peripheral blood (PB) were studied in 50 patients with high-grade non-Hodgkin's lymphoma enrolled in a phase III trial of intensive weekly chemotherapy (VAPEC- B) alone or with granulocyte colony-stimulating factor (G-CSF). Mononuclear cells numbers were monitored and their in vitro growth potential assessed in clonogenic progenitor cell assays and in long- term culture. Total colony-forming cells (granulocyte-macrophage [GM], burst-forming unit, erythroid [BFU-E], Mix-CFC) were increased 40-fold (median) over baseline with chemotherapy alone and 106-fold with chemotherapy and G-CSF after the final dose. CD34+ cells were increased to a median of 4%, equivalent to that in normal bone marrow (BM) controls. Circulating colony-forming cell levels were maximal when the recovering total white blood cell (WBC) count reached 5 to 10 x 10(9)/L. The timing of the maximum was reproducible in individual patients. Therefore the WBC count can be used as a guide to the timing of leukapheresis. PB cells from normal controls' and patients' prechemotherapy were unable to sustain hemopoiesis in two-stage long- term cultures. In contrast, PB cells collected from patients primed with chemotherapy alone or chemotherapy with G-CSF at the time of predicted maximal colony-forming cell release were able to generate and sustain hematopoiesis in long-term cultures at a level comparable or superior to normal BM. These findings indicate that the use of G-CSF after routine outpatient chemotherapy stimulates maximal release of primitive hemopoietic cells into the circulation, including colony- forming cells and long-term culture-initiating cells. Their numbers are comparable with those in normal BM and are such that a single leukapheresis will usually yield enough cells for hemopoietic reconstitution after myeloablative chemotherapy. 相似文献
93.
94.
95.
Chemokine receptor CCR7 enhances intrahepatic and lymphatic dissemination of human hepatocellular cancer 总被引:6,自引:0,他引:6
Schimanski CC Bahre R Gockel I Junginger T Simiantonaki N Biesterfeld S Achenbach T Wehler T Galle PR Moehler M 《Oncology reports》2006,16(1):109-113
Despite many pathophysiological analyses, the process of tumor dissemination of hepatocellular carcinoma (HCC) remains vague. In diverse tumor entities, expression of the chemokine receptor, CCR7, has been linked to tumor dissemination and poor prognosis. Therefore, we evaluated, whether CCR7 exerts similar effects in human HCC. CCR7 expression analysis was performed in vitro on human hepatoma cell lines (Huh7, Hep3B, wt HepG2, p53 dominant negative transfected HepG2). In addition, CCR7 expression was evaluated in 39 patients with hepatocellular cancer and correlated with both, tumor and patients characteristics. Human hepatocellular carcinoma samples and hepatoma cell lines displayed variable intensities of CCR7 expression. In patients, CCR7 expression was significantly associated with progressed local tumors (P = 0.02) and lymphatic metastasis (P = 0.02). Strong expression of CCR7 promotes intrahepatic and lymphatic HCC dissemination. 相似文献
96.
Thomas C. Wehler Swaantje Hamdi Annett Maderer Claudine Graf Ines Gockel Irene Schmidtmann Michael Hainz Martin R. Berger Matthias Theobald Peter R. Galle Markus Moehler Carl C. Schimanski 《International journal of colorectal disease》2013,28(3):385-398
Background
We initiated this preclinical study in order to analyze the impact of sorafenib single treatment versus combination treatment in human colorectal cancer.Methods
The effect of increasing sorafenib doses on proliferation, apoptosis, migration, and activation of signal cascades was analyzed in vitro. The effect of sorafenib single treatment versus 5-fluorouracil (5-FU) single treatment and combination therapy on in vivo proliferation and target cytokine receptor/ligand expression was analyzed in a human colon cancer xenograft mouse model using HT29 tumor cells.Results
In vitro, SW480 and HT29 cell lines were sensitive to sorafenib, as compared to Caco2 and SW620 cell lines, independent of the mutation status of K-ras, Raf, PTEN, or PI3K. The effect on migration was marginal, but distinct differences in caspases activation were seen. Combination strategies were beneficial in some settings (sorafenib?+?5-FU; irinotecan) and disadvantageous in others (sorafenib?+?oxaliplatin), depending on the chemotherapeutic drug and cell line chosen. Sensitive cell lines revealed a downregulation of AKT and had a weak expression level of GADD45β. In resistant cell lines, pp53 and GADD45β levels decreased upon sorafenib exposure. In vivo, the combination treatment of sorafenib and 5-FU was equally effective as the respective monotherapy concerning tumor proliferation. Interestingly, treatment with either sorafenib or 5-FU resulted in a significant decrease of VEGFR1 and PDGFRβ expression intensity.Conclusions
In colorectal cancer, a sensitivity towards sorafenib exists, which seems similarly effective as a 5-FU monotherapy. A combination therapy, in contrast, does not show any additional effect. 相似文献97.
Volker Heinemann Ludwig Fischer von Weikersthal Thomas Decker Alexander Kiani Florian Kaiser Salah-Edin Al-Batran Tobias Heintges Christoph Lerchenmüller Christoph Kahl Gernot Seipelt Frank Kullmann Markus Moehler Werner Scheithauer Swantje Held Lisa Miller-Phillips Dominik Paul Modest Andreas Jung Thomas Kirchner Sebastian Stintzing 《British journal of cancer》2021,124(3):587
Background Cetuximab plus FOLFIRI improved overall survival compared with bevacizumab plus FOLFIRI in KRAS wild-type metastatic colorectal cancer (mCRC) in FIRE-3, but no corresponding benefit was found for progression-free survival. This analysis aimed to determine whether cetuximab improves response and survival versus bevacizumab among response-evaluable patients receiving first-line FOLFIRI for RAS wild-type mCRC and the effect of primary tumour side on outcomes.Methods The intent-to-treat population included 593 patients with KRAS exon 2 wild-type mCRC. Further testing identified 400 patients with extended RAS wild-type disease; of these, 352 (88%) who received ≥3 cycles of therapy and had ≥1 post-baseline scan were evaluable for response and constituted the per-protocol population (169 cetuximab and 183 bevacizumab). Patients received 5-fluorouracil, folinic acid and irinotecan (FOLFIRI) with either weekly cetuximab or biweekly bevacizumab given on day 1 of each 14-day cycle until response, progression or toxicity occurred. The primary endpoint was the objective response rate (ORR) in the per-protocol population. Secondary endpoints included overall survival (OS) and progression-free survival (PFS). The effect of primary tumour location was evaluated.Results Median OS in the RAS wild-type population was 31 vs 26 months in the cetuximab and bevacizumab groups, respectively (HR 0.76, P = 0.012). In the per-protocol population, outcomes favoured cetuximab for ORR (77% vs 65%, P = 0.014) and median OS (33 vs 26 months, HR 0.75, P = 0.011), while PFS was comparable between groups. The advantage of cetuximab over bevacizumab occurred only in patients with left-sided primary tumours.Conclusions FOLFIRI plus cetuximab resulted in a significantly higher ORR and longer OS compared to FOLFIRI plus bevacizumab among patients with left-sided tumours. The superior response associated with cetuximab may particularly benefit patients with symptomatic tumours or borderline-resectable metastases.ClinicalTrials.gov identifier .Subject terms: NCT00433927Oncology, Biomarkers 相似文献
98.
99.
Gustavo Werutsky Michel Ducreux Manfred Lutz Murielle Mauer Eric Van Cutsem Theo Ruers Gunnar Folprecht Markus Moehler Daniela Aust Jean-Luc Van Laethem Florian Lordick Bernard Nordlinger Arnaud Roth 《European Journal of Cancer Supplements》2012,10(1):51-57
During the last decades, the evolution of treatment - including radiotherapy, chemotherapy and targeted agents - has improved the cure and survival of patients with gastrointestinal (GI) cancer. Within the past 50 years of the EORTC's existence, significant progress has been made in the fight against cancer. During this time several cancer clinical trials were completed, and through these we are able to identify the most notable advances in GI cancer research done by the EORTC Gastrointestinal Tract Cancer Group (GI Group). Several EORTC clinical trials results have changed practice (e.g. standard of care of liver metastases of colorectal cancer has been changed by the EPOC trial) or have helped to support new treatment strategies in either early- or advanced-stage GI cancers. In addition to its clinical activities the group has started an extensive program of translational research. This changed strategy towards a translational, multidisciplinary program regarded as the basis for future developments. This review of the major achievements of the GI Group shows that it has played an important role in the scientific development of the understanding and treatment of GI cancer over the last 50 years. 相似文献
100.
T Trarbach M Moehler V Heinemann C-H K?hne M Przyborek C Schulz V Sneller G Gallant S Kanzler 《British journal of cancer》2010,102(3):506-512